325 related articles for article (PubMed ID: 33022197)
1. Evaluating the Safety and Efficacy of a Topical Formulation Containing Epidermal Growth Factor, Tranexamic Acid, Vitamin C, Arbutin, Niacinamide and Other Ingredients as Hydroquinone 4% Alternatives to Improve Hyperpigmentation: A Prospective, Randomized, Controlled Split Face Study.
Kalasho BD; Minokadeh A; Zhang-Nunes S; Zoumalan RA; Shemirani NL; Waldman AR; Pletzer V; Zoumalan CI
J Cosmet Sci; 2020; 71(5):263-290. PubMed ID: 33022197
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone.
Makino ET; Mehta RC; Garruto J; Gotz V; Sigler ML; Herndon JH
J Drugs Dermatol; 2013 Mar; 12(3):s21-6. PubMed ID: 23545929
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone.
Makino ET; Herndon JH; Sigler ML; Gotz V; Garruto J; Mehta RC
J Drugs Dermatol; 2012 Dec; 11(12):1478-82. PubMed ID: 23377519
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of hydroquinone-free and hydroquinone-based hyperpigmentation regimens in treating facial hyperpigmentation and photoaging.
Fabi SG; Goldman MP
J Drugs Dermatol; 2013 Mar; 12(3):S32-7. PubMed ID: 23545931
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a hydroquinone-free skin brightening product using in vitro inhibition of melanogenesis and clinical reduction of ultraviolet-induced hyperpigmentation.
Makino ET; Mehta RC; Banga A; Jain P; Sigler ML; Sonti S
J Drugs Dermatol; 2013 Mar; 12(3):s16-20. PubMed ID: 23545928
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of a novel multimodality hydroquinone-free skin brightener over six months.
Bruce S
J Drugs Dermatol; 2013 Mar; 12(3):S27-31. PubMed ID: 23545930
[TBL] [Abstract][Full Text] [Related]
7. A Randomized, Investigator-Blinded Comparison of Two Topical Regimens in Fitzpatrick Skin Types III-VI With Moderate to Severe Facial Hyperpigmentation.
Vanaman Wilson MJ; Jones IT; Bolton J; Larsen L; Wu DC; Goldman MP
J Drugs Dermatol; 2017 Nov; 16(11):1127-1132. PubMed ID: 29141061
[TBL] [Abstract][Full Text] [Related]
8. Randomized, Double-Blinded, Split-Face Study Comparing the Efficacy and Tolerability of Two Topical Products for Melasma.
Kaufman BP; Alexis AF
J Drugs Dermatol; 2020 Sep; 19(9):822-827. PubMed ID: 33026755
[TBL] [Abstract][Full Text] [Related]
9. Reduction in facial hyperpigmentation after treatment with a combination of topical niacinamide and tranexamic acid: a randomized, double-blind, vehicle-controlled trial.
Lee DH; Oh IY; Koo KT; Suk JM; Jung SW; Park JO; Kim BJ; Choi YM
Skin Res Technol; 2014 May; 20(2):208-12. PubMed ID: 24033822
[TBL] [Abstract][Full Text] [Related]
10. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation.
Grimes PE
Cutis; 2004 Dec; 74(6):362-8. PubMed ID: 15663072
[TBL] [Abstract][Full Text] [Related]
11. Split-face Evaluation of a Multi-ingredient Brightening Foam Versus a Reference Control in Women with Photodamaged Facial Skin.
Stephens TJ; Babcock M; Bucay V; Gotz V
J Clin Aesthet Dermatol; 2018 Oct; 11(10):24-28. PubMed ID: 30519376
[No Abstract] [Full Text] [Related]
12. Tolerance and efficacy of a product containing ellagic and salicylic acids in reducing hyperpigmentation and dark spots in comparison with 4% hydroquinone.
Dahl A; Yatskayer M; Raab S; Oresajo C
J Drugs Dermatol; 2013 Jan; 12(1):52-8. PubMed ID: 23377328
[TBL] [Abstract][Full Text] [Related]
13. The clinical benefit of a multimodal topical approach to treating skin dyspigmentation.
Draelos ZD; Diaz I
J Cosmet Dermatol; 2023 Jun; 22(6):1799-1804. PubMed ID: 37102219
[TBL] [Abstract][Full Text] [Related]
14. Brightening and Improvement of Facial Skin Quality in Healthy Female Subjects With Moderate Hyperpigmentation or Dark Spots and Moderate Facial Aging.
Serra M; Bohnert K; Narda M; Granger C; Sadick N
J Drugs Dermatol; 2018 Dec; 17(12):1310-1315. PubMed ID: 30586263
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of topical 5% cysteamine versus 4% hydroquinone in the treatment of facial melasma in women.
Lima PB; Dias JAF; Cassiano D; Esposito ACC; Bagatin E; Miot LDB; Miot HA
Int J Dermatol; 2020 Dec; 59(12):1531-1536. PubMed ID: 32864760
[TBL] [Abstract][Full Text] [Related]
16. Effect of a Tranexamic Acid, Kojic Acid, and Niacinamide Containing Serum on Facial Dyschromia: A Clinical Evaluation.
Desai S; Ayres E; Bak H; Manco M; Lynch S; Raab S; Du A; Green D; Skobowiat C; Wangari-Talbot J; Zheng Q
J Drugs Dermatol; 2019 May; 18(5):454-459. PubMed ID: 31141852
[TBL] [Abstract][Full Text] [Related]
17. Topical Cyperus rotundus essential oil for treatment of axillary hyperpigmentation: a randomized, double-blind, active- and placebo-controlled study.
Mohammed GF
Clin Exp Dermatol; 2022 Mar; 47(3):534-541. PubMed ID: 34618367
[TBL] [Abstract][Full Text] [Related]
18. Reduction in the appearance of facial hyperpigmentation after use of moisturizers with a combination of topical niacinamide and N-acetyl glucosamine: results of a randomized, double-blind, vehicle-controlled trial.
Kimball AB; Kaczvinsky JR; Li J; Robinson LR; Matts PJ; Berge CA; Miyamoto K; Bissett DL
Br J Dermatol; 2010 Feb; 162(2):435-41. PubMed ID: 19845667
[TBL] [Abstract][Full Text] [Related]
19. Quantification of Arbutin and its degradation products, hydroquinone and p-Benzoquinone, in hyperpigmentation topical formulation: Effect of extraction procedure and interference assessment.
Khadivi Y; Saeedpour M; Arjmandmazidi S; Nemati M; Monajjemzadeh F
J Pharm Biomed Anal; 2024 Aug; 246():116223. PubMed ID: 38763108
[TBL] [Abstract][Full Text] [Related]
20. A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
Wang J; Fabi S; Robinson D; Bajaj S; Geronemus R; Bell M; Widgerow A
J Drugs Dermatol; 2023 Apr; 22(4):333-338. PubMed ID: 37026875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
